ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Gilead invests in Arcus’s immunotherapy pipeline

by Michael McCoy
May 29, 2020 | APPEARED IN VOLUME 98, ISSUE 21

 

Gilead Sciences will invest $175 million in cash and $200 million in equity in Arcus Biosciences as part of a 10-year pact to develop cancer immunotherapies. The chemists Terry Rosen and Juan Jaen founded Arcus in 2015 after they sold Flexus Biosciences to Bristol-Myers Squibb for $800 million. Gilead will gain access to Arcus’s pipeline of small molecules and antibodies that target tumor evasion of the immune system as well as cancer growth and metastasis. Arcus will independently research new drug targets.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment